1. Home
  2. KVYO vs EXEL Comparison

KVYO vs EXEL Comparison

Compare KVYO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KVYO
  • EXEL
  • Stock Information
  • Founded
  • KVYO 2012
  • EXEL 1994
  • Country
  • KVYO United States
  • EXEL United States
  • Employees
  • KVYO N/A
  • EXEL N/A
  • Industry
  • KVYO
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KVYO
  • EXEL Health Care
  • Exchange
  • KVYO Nasdaq
  • EXEL Nasdaq
  • Market Cap
  • KVYO 8.8B
  • EXEL 9.4B
  • IPO Year
  • KVYO 2023
  • EXEL 2000
  • Fundamental
  • Price
  • KVYO $30.97
  • EXEL $36.70
  • Analyst Decision
  • KVYO Buy
  • EXEL Buy
  • Analyst Count
  • KVYO 19
  • EXEL 18
  • Target Price
  • KVYO $49.16
  • EXEL $37.59
  • AVG Volume (30 Days)
  • KVYO 1.5M
  • EXEL 2.7M
  • Earning Date
  • KVYO 05-07-2025
  • EXEL 04-29-2025
  • Dividend Yield
  • KVYO N/A
  • EXEL N/A
  • EPS Growth
  • KVYO N/A
  • EXEL 170.77
  • EPS
  • KVYO N/A
  • EXEL 1.76
  • Revenue
  • KVYO $937,464,000.00
  • EXEL $2,168,701,000.00
  • Revenue This Year
  • KVYO $26.40
  • EXEL $5.45
  • Revenue Next Year
  • KVYO $21.77
  • EXEL $10.32
  • P/E Ratio
  • KVYO N/A
  • EXEL $20.81
  • Revenue Growth
  • KVYO 34.29
  • EXEL 18.50
  • 52 Week Low
  • KVYO $21.26
  • EXEL $20.14
  • 52 Week High
  • KVYO $49.55
  • EXEL $40.02
  • Technical
  • Relative Strength Index (RSI)
  • KVYO 33.11
  • EXEL 48.90
  • Support Level
  • KVYO $32.06
  • EXEL $36.71
  • Resistance Level
  • KVYO $34.54
  • EXEL $38.41
  • Average True Range (ATR)
  • KVYO 1.49
  • EXEL 1.10
  • MACD
  • KVYO 0.17
  • EXEL -0.18
  • Stochastic Oscillator
  • KVYO 4.52
  • EXEL 21.43

About KVYO Klaviyo Inc. Series A

Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.

About EXEL Exelixis Inc.

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Share on Social Networks: